Welcome to the Working Group on New TB Drugs Blog
Posted in Announcements, TB Drug Development, TB News, TB Prevention and Control Strategies
TB Edition of The Lancet Infectious Diseases
To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.
Launch of the Good Participatory Practice Guidelines for TB Drug Trials
The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.
World TB Day Coverage: New Combo TB Drug Trial Announced
During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID).
Summary Available! TB Clinical Trials Consultants Meeting
On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.
First Novel Regimen Clinical Trial Featured on South African TB
The clinical trial of the first novel regimen was featured today on SABC TV in South Africa. This is the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001). The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an antibiotic commonly administered as part of current TB treatment.
TB Alliance Launches First Clinical Trial of a Novel TB Drug Regimen
Today, the TB Alliance announced the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001).The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an antibiotic commonly administered as part of current TB treatment. This regimen has shown potential to harmonize treatment for TB drug-sensitive tuberculosis (DS-TB) and multidrug-resistant tuberculosis (MDR-TB) under a single three-drug regimen.
This week in TB R&D – 10 August 2010
This week we reposted an article from DailyFinance.com regarding a new antibactierial compound from GlaxoSmithKline (GSK). GSK has recently published a Nature paper describing the 2.1 angstom crystal structure of Staphylococcus aureus DNA gyrase (a Type IIA topoisomerase) and DNA in complex with their new broad-spectrum antibacterial compound (GSK299423).
Impact of the CPTR Initiative
After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB.
Launch of the Critical Path to TB Drug Regimens
Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and advocates, and NGOs with the focus to accelerate the development of new, safe, and highly effective shorter length TB treatment regimens.
-
Toppix TB News- Effect of Isoniazid Shortage on TB Care 24 May 2013
- Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 23 May 2013
- Impact of a Shortage of First-Line Antituberculosis Medication on... 23 May 2013
- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
